Pharmacist's Application to Practice: Tremelimumab
November 10, 2022
Tremelimumab (IMJUDO, AztraZeneca Pharmaceuticals) approved November 10, 2022 for metastatic non-small cell lung cancer and approved October 24, 2022 for unresectable hepatocellular carcinoma